Regeneus and Cryosite have agreed to work together to develop and produce new stem cell products for clinical applications. Regeneus will provide the technology and resources to help Cryosite develop new ways to expand cord tissue-derived mesenchymal stem cells, and Cryosite will allow Regeneus to use its production facilities for Progenza, an allogeneic stem cell product for osteoarthritis.

Related Summaries